Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.59 |
| ▸ | COMT | P21964 | 1/20 | 0.54 |
| ▸ | MPO | P05164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MPI | P34949 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4016450 | 0.86 | DYRK1A (0.58) | DYRK1AMPOALDH1A1KDM4EPOLB | |
| SCHEMBL14723469 | 0.80 | DYRK1A (0.51) | DYRK1ACOMTMPOKDM4ENPC1 | |
| SCHEMBL28569504 | 0.78 | MKNK1 (0.56) | MPOALDH1A1LTA4HLMNAHPGD | |
| SCHEMBL5096786 | 0.78 | COMT (0.58) | DYRK1ACOMTALDH1A1KDM4EMPI | |
| SCHEMBL3499891 | 0.78 | HPGD (0.59) | COMTMPOALDH1A1HPGDMEN1 | |
| Hydrochloric Acid SCHEMBL17397945 | 0.76 | HPGD (0.57) | COMTMPOALDH1A1HPGDMEN1 | |
| SCHEMBL12703791 | 0.76 | HCAR2 (0.68) | COMT | |
| SCHEMBL27918312 | 0.75 | COMT (0.46) | COMTALDH1A1KDM4EMPIAPOBEC3G | |
| SCHEMBL1143140 | 0.75 | DYRK1A (1.00) | DYRK1AALDH1A1KDM4ELTA4HLMNA | |
| SCHEMBL22636476 | 0.74 | ALDH1A1 (0.47) | DYRK1ACOMTMPOALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105646358-B | A kind of synthetic method of 3 amino 5 (4 anisyl) pyrazoles | 苏州艾缇克药物化学有限公司 | 2018-03-09 | — | — | CN | claimed |
| CN-105646358-A | Synthesizing method of 3-amino-5-(4-methoxyphenyl) pyrazole | 苏州艾缇克药物化学有限公司 | 2016-06-08 | — | — | CN | claimed |
| CN-105646358-B | A kind of synthetic method of 3 amino 5 (4 anisyl) pyrazoles | 苏州艾缇克药物化学有限公司 | 2018-03-09 | — | — | CN | disclosed |
| CN-105646358-A | Synthesizing method of 3-amino-5-(4-methoxyphenyl) pyrazole | 苏州艾缇克药物化学有限公司 | 2016-06-08 | — | — | CN | disclosed |
| CN-103282034-A | Use of hematopoietic growth factor mimetics | LIGAND PHARM INC | 2013-09-04 | — | — | CN | disclosed |
| CN-102656141-A | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARM INC | 2012-09-05 | — | — | CN | disclosed |
| US-7393870-B2 | 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-20060074116-A1 | 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-04-06 | — | — | US | disclosed |
| US-7005444-B2 | 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2006-02-28 | — | — | US | disclosed |
| US-20030130328-A1 | 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6559173-B1 | organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. | ALLERGAN, INC. | 2003-05-06 | — | — | US | disclosed |
| WO-2003026650-A1 | 3-(HETEROARYLAMINO)METHYLENE-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074116-A1 | 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | DYRK1A 249/4885COMT 1581/4885MPO 4671/4885 |
| US-20030130328-A1 | 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | DYRK1A 249/4885COMT 1581/4885MPO 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.